First Patient Dosed in ProstACT Program for Prostate Cancer Therapy
Go back to First Patient Dosed in ProstACT Program for Prostate Cancer Therapy| TRANS-LUX CORPORATION (NASDAQ: TLX) | Delayed: 9.14 -0.37 (3.89%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $9.51 | 52 Week High | $2.18 | |||
| Open | $9.26 | 52 Week Low | $0.30 | |||
| Day High | $9.26 | P/E | N/A | |||
| Day Low | $9.14 | EPS | $-3.32 | |||
| Volume | 50,742 | |||||



